IPO - Rhythm Biosciences Limited, page-95

well maybe before you make comment you should investigate this properly. They aren't going for the FDA they are going for European and Aus/NZ approval, much faster and easier. 1000 patients is not onerous considering how many colonoscopies and FIT studies are done on a weekly basis.

with an EV of around 20 mill with the potential to disrupt the bowel cancer screening market this is still very cheap.

The one thing you did get correct is there will be a 2 year period before it hits the market but there should be many rerating events along the way . I personally don't see them lasting the 2 years, a large diagnostic specialist company like say a Roche or someone like that will jump all over them.